Advances in Clostridioides difficile therapeutics
Advances in Clostridioides difficile therapeutics
复制标题
艰难梭菌治疗的进展
DOI：
--
复制
发表时间：
2021
影响因子：
5.7
通讯作者：
S. Khanna
中科院分区：
文献类型：
--
作者：
S. Khanna
艰难梭菌是医院中最常见的病原体，并且社区获得性感染的风险增加，因此是一个紧迫的公共卫生威胁[1]。在美国，艰难梭菌感染 (CDI) 的发病率随着复发性 CDI 的不成比例上升而增加。 CDI 的主要危险因素是抗生素暴露、高龄、存在免疫抑制、炎症性肠病、慢性肾病等合并症[1]。原发性和复发性 CDI 的病理生理学包括肠道微生物群的破坏，即菌群失调。 CDI 的临床特征包括腹泻、腹痛、发热到伴有严重败血症的暴发性结肠炎。初始 CDI 治疗的基石是抗生素治疗，多重复发性 CDI 则通过微生物组恢复疗法进行治疗，以恢复肠道菌群失调 [1]。本文讨论原发性和复发性 CDI 诊断和治疗的最新进展。
Clostridioides difficile is an urgent public health threat by virtue of being the most common pathogen in hospitals and an increased risk of community-acquired infection [1]. The incidence of Clostridioides difficile infection (CDI) is increasing with a disproportionate rise in recurrent CDI seen in the United States. The primary risk factors for CDI are antibiotic exposure, advanced age, presence of comorbid conditions such as immunosuppression, inflammatory bowel disease, chronic kidney disease, amongst others [1]. The pathophysiology of both primary and recurrent CDI includes a disruption of the gut microbiota, i.e. dysbiosis. The clinical features of CDI range from diarrhea, abdominal pain, fever to fulminant colitis with severe sepsis. The cornerstone of the management of initial CDI is an antibiotic therapy and multiply recurrent CDI is managed with microbiome restoration therapies to restore gut dysbiosis [1]. This article discusses recent advances in the diagnosis and therapy of primary and recurrent CDI.
影响因子：
11.8
作者：
McDonald, L. Clifford;Gerding, Dale N.;Wilcox, Mark H.
通讯作者：
Wilcox, Mark H.